Neuromuscular Disease

Date/Time: Monday, October 24, 2022 - 3:45 PM – 5:45 PM
Track: Traditional Special Interest Group
Log in to Add to My Schedule


This special interest group session will focus on three areas of contemporary interest in neuromuscular disease.  One session will review muscular dystrophies and examine the recent development and release of several novel therapies for treatment of muscular dystrophies. Another session will review the challenges of therapy development for ALS, particularly for the genetic forms.  The third session will focus on the expanding number of recognized autoantibodies in peripheral neuropathy and discuss the testing and implications for diagnosis and treatment in this heterogeneous group of neuropathies. Three short presentations will be selected from the best accepted neuromuscular abstracts.

Chair: Michelle Mauermann, MD, FANA

Co-Chair: Teerin Liewluck, MD


At the conclusion of the activity, participants will be able to:

  • Identify the antibodies associated with specific peripheral neuropathy phenotypes;
  • Describe treatment strategies for distinct autoimmune neuropathy syndromes; 
  • Identify novel therapies for muscular dystrophies
  • Identify novel therapies for genetic forms of ALS
  • Recognize the challenges of therapy development in amyotrophic lateral sclerosis

Treatment Update for Muscular Dystrophies


Evolving Paradigms in ALS Therapy Development


Antibody Testing in Peripheral Neuropathy


Disease-Responsive Gene Therapy for the Treatment of Myotonic Dystrophy

Poster Presenter: Samuel Carrell, MD, PhD, University of Pennsylvania

The Genome, Epigenome, and Schwann Cell Transcriptome Implicate the Immune System as a Mediator of Neuropathy in Both Patients and Murine Models

Poster Presenter: Stephanie Eid, PhD, University of Michigan

Safety and Activity of Anti-CD14 Antibody IC14 (Atibuclimab) in ALS: Experience with an Expanded Access Protocol

Poster Presenter: Dario Gelevski, Healey Center at Mass General Hospital